ArticleJournal of biomedical optics2012
Improved tumor contrast achieved by single time point dual-reporter fluorescence imaging.
Article in Journal of biomedical optics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 67 citations in OpenAlex.
- Whole-body tomographic fluorescence lifetime imaging of PD-L1 expression.Research square · 2026Article
- TRIPODD Enables Single-Cell Quantification of Therapeutic Efficacy.Molecular pharmaceutics · 2026Article
- A multi-channel fluorescence endoscope for pre-operative assessment of epithelial ovarian cancer.Proceedings of SPIE--the International Society for Optical Engineering · 2026Article
- Dynamic Tracking ofMolecular pharmaceutics · 2025Article
- Quantitative pharmacokinetic and biodistribution studies for fluorescent imaging agents.Biomedical optics express · 2024Article
- Article
- Improved Discrimination of Tumors with Low and Heterogeneous EGFR Expression in Fluorescence-Guided Surgery Through Paired-Agent Protocols.Molecular imaging and biology · 2023Article
- Rapid and Quantitative Intraoperative Pathology-Assisted Surgery by Paired-Agent Imaging-Derived Confidence Map.Molecular imaging and biology · 2023Article
- Identification of a Suitable Untargeted Agent for the Clinical Translation of ABY-029 Paired-Agent Imaging in Fluorescence-Guided Surgery.Molecular imaging and biology · 2023Article
- Paired-agent imaging as a rapidFrontiers in oncology · 2023Article
- Fluorescence molecular optomic signatures improve identification of tumors in head and neck specimens.Frontiers in medical technology · 2023Article
- Comparison of cRGDfK Peptide Probes with Appended Shielded Heptamethine Cyanine Dye (ACS omega · 2021Article
- TRIPODD: a Novel Fluorescence Imaging Platform for In Situ Quantification of Drug Distribution and Therapeutic Response.Molecular imaging and biology · 2021Article
- Intraoperative Detection of Micrometastases in Whole Excised Lymph Nodes Using Fluorescent Paired-Agent Imaging Principles: Identification of a Suitable Staining and Rinsing Protocol.Molecular imaging and biology · 2021Article
- Is Tumor Cell Specificity Distinct from Tumor Selectivity In Vivo?: A Quantitative NIR Molecular Imaging Analysis of Nanoliposome Targeting.Nano research · 2021Article
- Development of a drug-device combination for fluorescence-guided surgery in neuroendocrine tumors.Journal of biomedical optics · 2020Article
- Prediction of optimal contrast times post-imaging agent administration to inform personalized fluorescence-guided surgery.Journal of biomedical optics · 2020Article
- Paired Agent Fluorescence Imaging of Cancer in a Living Mouse Using Preassembled Squaraine Molecular Probes with Emission Wavelengths of 690 and 830 nm.Bioconjugate chemistry · 2020Article
- Intracellular paired agent imaging enables improved evaluation of tyrosine kinase inhibitor target engagement.Proceedings of SPIE--the International Society for Optical Engineering · 2020Article
- Task-based evaluation of fluorescent-guided cancer surgery as a means of identifying optimal imaging agent properties in the context of variability in tumor- and healthy-tissue physiology.Proceedings of SPIE--the International Society for Optical Engineering · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
In this study, we demonstrate a method to quantify biomarker expression that uses an exogenous dual-reporter imaging approach to improve tumor signal detection. The uptake of two fluorophores, one nonspecific and one targeted to the epidermal growth factor receptor (EGFR), were imaged at 1 h in three types of xenograft tumors spanning a range of EGFR expression levels (n=6 in each group). Using this dual-reporter imaging methodology, tumor contrast-to-noise ratio was amplified by >6 times at 1 h postinjection and >2 times at 24 h. Furthermore, by as early as 20 min postinjection, the dual-reporter imaging signal in the tumor correlated significantly with a validated marker of receptor density (P<0.05, r=0.93). Dual-reporter imaging can improve sensitivity and specificity over conventional fluorescence imaging in applications such as fluorescence-guided surgery and directly approximates the receptor status of the tumor, a measure that could be used to inform choices of biological therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.